Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (27)

I-05

Impact of maternal zidovudine infusions at labor on fetus: a population pharmacokinetic study

Wednesday 10:20-11:50

I-08Aline Fuchs

Impact of medication adherence measurement on antiretroviral drug pharmacokinetics: A retrospective cohort study in HIV patients followed by therapeutic drug monitoring and taking part in a medication-adherence enhancing program

Wednesday 10:20-11:50

I-16Sandra Gil

Modeling the Postantifungal Effect of Anidulafungin Against Candida

Wednesday 10:20-11:50

I-50Ron Keizer

Expected effectiveness of reduced-dose efavirenz

Wednesday 10:20-11:50

I-51David Khan

Evaluation of Mechanism Based PKPD Model for Antibiotics

Wednesday 10:20-11:50

II-03

Population modelling and simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of isoniazid in lungs

Wednesday 15:10-16:30

II-04Cédric Laouenan

Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir and Peg-IFN during triple therapy in treatment-experienced HCV infected cirrhotic patients

Wednesday 15:10-16:30

II-27Iris Minichmayr

Target site pharmacokinetics of doripenem in plasma and interstitial space fluid of peripheral tissues

Wednesday 15:10-16:30

II-40

Population pharmacokinetics of ALX-0171, an inhaled Respiratory Syncytial Virus (RSV) neutralizing Nanobody.

Wednesday 15:10-16:30

II-52Gauri Rao

Characterization of Oseltamivir Carboxylate (OC) Disposition using a Reduced Population (POP) Pharmacokinetic (PK) Model

Wednesday 15:10-16:30

II-60Adedeji Majekodunmi

Mixed Effect Modelling in HCV-HIV co-infected Children

Wednesday 15:10-16:30

III-07Natalia Aniceto

Population Pharmacokinetics-Pharmacogenetics of Efavirenz using Non-Linear Mixed Effects Modeling and Bayesian Estimation

Thursday 10:05-11:30

III-08Manel Aouri

Population pharmacokinetics and pharmacogenetics analysis of Rilpivirine in HIV-1 infected individuals

Thursday 10:05-11:30

III-09Eduardo Asín-Prieto

Population Pharmacokinetics of Daptomycin in Critically Ill Patients

Thursday 10:05-11:30

III-12Ana Bastos

Modeling and simulation of temocillin (TMO) in patients with end stage renal disease undergoing haemodialysis

Thursday 10:05-11:30

III-16Andrzej Bienczak

Population Pharmacokinetic Analysis of Efavirenz in African Children using mixture modelling to describe clearance multimodality.

Thursday 10:05-11:30

III-28Jantine Brussee

Modelling and simulation of the effect of L-arginine adjunctive therapy on vascular function in patients with moderately severe malaria

Thursday 10:05-11:30

III-33Aziz Chaouch

Population pharmacokinetics of oral voriconazole patients undergoing cataract surgery: modelling concentrations in plasma and in the aqueous humour

Thursday 10:05-11:30

III-35Chunli Chen

Population pharmacokinetic-pharmacodynamic modelling of rifampicin treatment response in a tuberculosis acute mouse model

Thursday 10:05-11:30

III-47Paola Coppola

Pharmacokinetic assessment of prulifloxacin in patients with renal impairment using population pharmacokinetics modelling and simulations

Thursday 10:05-11:30

III-52Paolo Denti

Population pharmacokinetics of cefazolin in children undergoing elective cardiac surgery

Thursday 10:05-11:30

IV-15Konstantina Soulele

A population pharmacokinetic study of fluticasone/salmeterol in healthy subjects using two different dry powder inhalers

Thursday 15:15-16:40

IV-16Christine Staatz

A survey of intravenous tobramycin monitoring and dosage adjustment practice in cystic fibrosis patients in Australia and the United Kingdom

Thursday 15:15-16:40

IV-33Elodie Valade

Modified renal function in pregnancy: impact on emtricitabine pharmacokinetics

Thursday 15:15-16:40

IV-36Coen van Hasselt

Development of an integrated model-based framework to support clinical development of antibiotics

Thursday 15:15-16:40

IV-39Rob van Wijk

Challenges in the evaluation of the preclinical dosing rationale for tuberculosis treatment

Thursday 15:15-16:40

IV-52Hinojal Zazo Gómez

PK/PD modelling and simulation of stavudine nanoparticles in HIV patients

Thursday 15:15-16:40